These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26446380)

  • 1. Segmental pityriasis rosea within the area of BRAF-mutated metastatic melanoma.
    Murad A; Ralph N; Mulligan N; Moloney FJ
    J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e133-e134. PubMed ID: 26446380
    [No Abstract]   [Full Text] [Related]  

  • 2. Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.
    Saint-Jean M; Quereux G; Nguyen JM; Peuvrel L; Brocard A; Vallee A; Knol AC; Khammari A; Denis MG; Dréno B
    Oncol Rep; 2014 Aug; 32(2):808-14. PubMed ID: 24926836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narrative review: BRAF opens the door for therapeutic advances in melanoma.
    Flaherty KT
    Ann Intern Med; 2010 Nov; 153(9):587-91. PubMed ID: 21041578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
    Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
    J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.
    Gummadi T; Zhang BY; Valpione S; Kim C; Kottschade LA; Mittapalli RK; Chiarion-Sileni V; Pigozzo J; Elmquist WF; Dudek AZ
    Melanoma Res; 2015 Feb; 25(1):75-9. PubMed ID: 25426645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of BRAF mutation in metastatic melanoma utilizing cell-transferred cytological smears.
    Chen S; Randolph M; Cramer HM; Watkins T; McCullough H; Post KM; Sen JD; Cheng L; Wu HH
    Acta Cytol; 2014; 58(5):478-82. PubMed ID: 25359156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.
    Garrisi VM; Strippoli S; De Summa S; Pinto R; Perrone A; Guida G; Azzariti A; Guida M; Tommasi S
    PLoS One; 2014; 9(12):e112025. PubMed ID: 25437182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma.
    Sebaratnam DF; Martin LK; Venugopal SS; Mangos G; Freiman J; de Souza P; Farnsworth A; Cheung K; Scolyer RA; Murrell DF
    Int J Dermatol; 2014 Nov; 53(11):1409-11. PubMed ID: 25257244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
    Kim GH; Levy A; Compoginis G
    J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
    Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
    Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.
    Sondak VK; Smalley K
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):386-7. PubMed ID: 19624312
    [No Abstract]   [Full Text] [Related]  

  • 17. Inducible BRAF suppression models for melanoma tumorigenesis.
    Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
    Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
    Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
    Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.